Patent Attorney Trainee
Marco focuses on post-grant proceedings of European patents at the European Patent Office (EPO), German patents at the German Federal Patent Court, and patent infringement proceedings before national German courts. He leverages his training in molecular biology and experience in the pharmaceutical, biotechnology and medical device industries to work on cases across the life sciences sector, including biotechnology, biologics, pharmaceuticals, medical devices, and diagnostics.
Earlier in his legal career, Marco gained in-house patent prosecution and management experience related to biologics and medical devices at an innovative biotechnology company. He held several managerial positions in research and development, quality control and quality assurance departments.
Marco was trained as a biologist and molecular biologist at the Leopold Franzens University in Innsbruck (Austria), including working as a scientific staff employee at the Daniel Swarovski Research Laboratory. His master thesis project was in the fields of molecular oncology and transplantation research. Following his MSc studies, Marco pursued a PhD at the Medical University of Innsbruck in Molecular Cell Biology and Oncology and conducted research in the field of stem cell biology.
Innovacell AG v. University of Pittsburgh*
T 0527/17, EPO
Innovacell Biotechnologie AG v. University of Pittsburgh*
T 1031/16, EPO
Innovacell Biotechnologie AG v. University of Pittsburgh*
T 1050/12, EPO
Articles
Unified Patent Court Offers Far-reaching Opportunities for MedTech Companies Unified Patent Court Offers Far-reaching Opportunities for MedTech Companies
September 19, 2023
DeviceMedEvent
UK BioIndustry Association Summer Party 2023 UK BioIndustry Association Summer Party 2023
July 13, 2023
London
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.